Catalyst Pharmaceuticals Inc (CPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has a cash flow conversion efficiency ratio of 0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($59.59 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Catalyst Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Catalyst Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Catalyst Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Catalyst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand Canyon Education Inc
NASDAQ:LOPE
|
0.127x |
|
Fujian Anjoy Foods Co Ltd
SHG:603345
|
0.076x |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
-0.010x |
|
Indorama Ventures PCL
BK:IVL
|
0.120x |
|
flatexDEGIRO AG
XETRA:FTK
|
1.644x |
|
LivaNova PLC
NASDAQ:LIVN
|
0.013x |
|
AMP Ltd
AU:AMP
|
-0.316x |
|
IONOS GROUP N
XETRA:IOS
|
0.288x |
Annual Cash Flow Conversion Efficiency for Catalyst Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Catalyst Pharmaceuticals Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Catalyst Pharmaceuticals Inc (CPRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $954.27 Million | $208.67 Million | 0.219x | -33.65% |
| 2024-12-31 | $727.63 Million | $239.81 Million | 0.330x | -10.98% |
| 2023-12-31 | $387.88 Million | $143.60 Million | 0.370x | -4.16% |
| 2022-12-31 | $300.42 Million | $116.05 Million | 0.386x | +32.34% |
| 2021-12-31 | $206.83 Million | $60.37 Million | 0.292x | +9.92% |
| 2020-12-31 | $169.60 Million | $45.03 Million | 0.266x | -32.77% |
| 2019-12-31 | $87.63 Million | $34.61 Million | 0.395x | +178.03% |
| 2018-12-31 | $50.78 Million | $-25.70 Million | -0.506x | -198.20% |
| 2017-12-31 | $80.96 Million | $-13.74 Million | -0.170x | +62.86% |
| 2016-12-31 | $39.31 Million | $-17.96 Million | -0.457x | -40.72% |
| 2015-12-31 | $55.48 Million | $-18.02 Million | -0.325x | +11.57% |
| 2014-12-31 | $35.24 Million | $-12.94 Million | -0.367x | +20.46% |
| 2013-12-31 | $21.39 Million | $-9.88 Million | -0.462x | -31.32% |
| 2012-12-31 | $14.62 Million | $-5.14 Million | -0.352x | +73.48% |
| 2011-12-31 | $3.76 Million | $-4.99 Million | -1.326x | -94.66% |
| 2010-12-31 | $5.52 Million | $-3.76 Million | -0.681x | +32.48% |
| 2009-12-31 | $7.62 Million | $-7.68 Million | -1.009x | -28.94% |
| 2008-12-31 | $10.56 Million | $-8.26 Million | -0.782x | -188.55% |
| 2007-12-31 | $16.32 Million | $-4.42 Million | -0.271x | -356.52% |
| 2006-12-31 | $19.85 Million | $-1.18 Million | -0.059x | +94.18% |
| 2005-12-31 | $446.46K | $-455.36K | -1.020x | +47.98% |
| 2004-12-31 | $117.58K | $-230.52K | -1.961x | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more